logo-loader
viewOpen Orphan PLC

Open Orphan to become '$1bln firm in very near future' after COVID-19 study receives ethics approval

Open Orphan PLC's (LON:ORPH) Cathal Friel talks to Proactive London's Katie Pilbeam about the world’s first COVID-19 characterisation study receiving approval from a specially convened Research Ethics Committee (REC). 

This follows a contract received by the company’s subsidiary hVIVO from the UK government to develop a COVID-19 human challenge study model.

Friel explains that the vaccines industry has been the 'cinderella' of the sector for so many years, but is now growing fast.

Quick facts: Open Orphan PLC

Price: 29 GBX

AIM:ORPH
Market: AIM
Market Cap: £194.13 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Market Report: FTSE gains as hopes rise of UK and France solving port chaos

FTSE 100 edged higher as France and the UK said they were near to ending the freight ban which has led to hundreds of lorries queuing outside Dover. London’s blue-chip index added 13 to 6,429 in spite of rising concerns over the new strain of COVID-19.   Mixed news for the UK economy...

on 22/12/20

2 min read